# Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

> **NCT06341764** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 38 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Durvalumab 1120 mg
- **DRUG:** Durvalumab 1500 mg
- **DRUG:** Tremelimumab i.v. at 300 mg
- **COMBINATION_PRODUCT:** Cisplatin (CDDP) 25 mg/mq i.v
- **COMBINATION_PRODUCT:** Gemcitabine (GEM) 1000 mg/mq i.v.

## Key facts

- **NCT ID:** NCT06341764
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06341764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06341764, "Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06341764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*